argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease

Impact · against what's priced in

The discontinuation of the Phase 3 UNITY study in Sjögren's disease is a negative catalyst for argenx, though its impact is tempered by the fact that the market was already discounting much of the pipeline's broader potential. Halozyme faces negligible impact as its revenue is tied to the broader commercial success of the Vyvgart franchise rather than a single pipeline indication.

ARGX−0.40

Not in the price yet

In context

The discontinuation of the Phase 3 UNITY study due to futility removes a potential growth driver. While the market is already skeptical of some pipeline assets, this confirms a total loss of value for the Sjögren's indication.